Q1 2025 Zevra Therapeutics Inc Earnings Call Transcript
Key Points
- Zevra Therapeutics Inc (ZVRA) exceeded internal expectations for the MIPLYFFA launch, enrolling over one-third of diagnosed Niemann-Pick disease type C (NPC) patients in the US.
- The company added $148.3 million of non-dilutive capital to its balance sheet through the monetization of a pediatric rare disease Priority Review Voucher, enhancing financial strength.
- Zevra Therapeutics Inc (ZVRA) was recognized on Fast Company's Top 10 Most Innovative Companies list in the medicines, therapeutics, and pharmaceuticals category.
- The Phase 3 DISCOVER trial for Celiprolol, targeting Vascular Ehlers-Danlos syndrome (VEDS), is progressing with patient enrollments, supported by Orphan Drug and Breakthrough Therapy designations.
- The company is actively expanding MIPLYFFA's availability outside the US, with plans for a Marketing Authorization Application in Europe, targeting approximately 1,100 people living with NPC.
- Despite the progress, Zevra Therapeutics Inc (ZVRA) faces challenges with payer reimbursement, with only 38% of covered lives achieved for MIPLYFFA.
- The launch of OLPRUVA has been slower than expected, with only 28 prescription enrollment forms received since its availability in July 2023.
- The company reported a net loss of $3.1 million for the first quarter of 2025, although this was an improvement from the previous year.
- Zevra Therapeutics Inc (ZVRA) is facing challenges in enrolling patients for the Phase 3 DISCOVER trial for Celiprolol, with only 32 patients enrolled out of a target of 150.
- The company has moderated expectations for OLPRUVA's launch pace due to unique dynamics in the UCD commercial landscape, indicating potential hurdles in market penetration.
Good afternoon and thank you for joining Zevra's first-quarter 2025 financial results and corporate update conference call. Today's call is being recorded and will be available via the Investor Relations section of the company's website later today. The host for today's call is Nichol Ochsner, Zevra's Vice President. Please go ahead.
Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of first-quarter financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the Investor section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements.
Actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties associated with Zevra's business. Forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
